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Letters to the Editor
Aripiprazole Decreases Irritability in 12 out of 14 Youth
with Autism Spectrum Disorders
Ann Maloney, MD, Eric O. Mick, ScD, and Jean Frazier, MD
To The Editor:
Autism is a neurodevelopment disorder characterized bylifelong impairments. Youth with autism spectrum disorders
(ASDs) are often prescribed medication treatments to help with
maladaptive behaviors (Campbell et al 1978; Cohen et al. 1980;
Naruse et al. 1982; Anderson et al. 1984; McDougle et al. 1998;
Aman et al. 2005; Chavez et al. 2007; Doyle and McDougle 2012).
Both aripiprazole and risperidone have been approved by the
United States Food and Drug Administration (FDA) to treat the
irritability of autism, and short-term studies have demonstrated
safety and preliminary efficacy. In 2006, the FDA approved ris-
peridone for the treatment of irritability in youth with autism based
on two, 8 week randomized controlled trials (McCracken et al.
2002; Shea et al. 2004). The FDA then approved aripiprazole in
2009 for treating irritability in youth with autism, who were be-
tween the ages 6 and 17 years (Owen et al. 2009).
Aripiprazole has a unique mechanism of action, as it has a
combination of partial agonism at the D2 and 5-HT1A receptors
and antagonism at the 5-HT2A receptor. In addition, aripiprazole
only has moderate H1 affinity, which may lessen attendant weight
gain and sedation compared with other medications in the class.
We conducted an open-label study of aripiprazole in youth with
ASDs over a 12 week period, to test its effectiveness and safety in
youth 7–14 years of age. The protocol was institutional review
board (IRB) approved by the Cambridge Health Alliance (trial
registered at NCT00308074). Parents signed informed consent
and youth signed assent forms prior to enrollment. Whereas in
prior registration 8 week studies, doses ranged from 2.5 to 15mg/
day, we permitted a daily maximum of 20mg/day in divided
doses. Our study permitted flexible dosing allowing for 2.5–5mg
uptitration on a weekly basis to reduce irritability, with a goal of
prescribing the lowest effective dose to minimize side effects.
The study population was boys or girls between the ages of 6 and
17 years with a diagnosis of autism, Asperger’s disorder, or per-
vasive developmental disorder, not-otherwise-specified (PDD
NOS) based on American Psychiatric Association, Diagnostic and
Statistical Manual of Mental Disorders, 4th ed., Text Revision
(DSM-IV-TR) and confirmed using both the Autism Diagnostic
Observation Schedule (ADOS) and the Autism Diagnostic Inter-
view-Revised (ADI-R) (Lord and Le Couteur 1994; American
Psychiatric Association 2000). To be included in this study, a sub-
ject had to have a minimum score of 18 on the irritability subscale
of the Aberrant Behavior Checklist-Irritability (ABC-Irritability)
subscale (which has a maximum of 45 points). All subjects had at
least a score of moderate on the Clinical Global Impressions Scale-
Severity (CGI-S) to be included. Exclusion criteria included any
other significant Axis I disorder, estimated intelligence quotient
(IQ) < 50, significant medical or neurologic illness, requiring other
psychotropic medications that could not be safely tapered, or in-
ability to manage blood draws. To be rated a clinical responder, a
subject had to have both a 25% reduction of the ABC-Irritability
(Aman et al. 1985) and a score of 1 or 2 (very much improved or
much improved) on the Clinical Global Impressions-Improvement
Scale (CGI-I). We used several safety measures, such as the Mon-
itoring of Side Effects System (MOSES), laboratory tests, vital
signs, and weight, to monitor for adverse effects on a weekly basis.
We report here on 14 children and adolescents, 8 of whom were
males (age 13 – 1.3 years) and 4 ofwhomwere females (age 12 – 2.3
years). Overall, 87.5% were treatment responders, and the average
end-point dose was 10.4 – 5.3mg at week 12 (see Table 1). Al-
though all subjects experienced improvement in CGI-I scores from
first to final visits, the mean end-point CGI-I score was 1.78 – 1.58.
There were two youth who did not meet response criteria. One had a
25% change in ABC-I but a CGI-Irritability score of 3, and the other
had a CGI-I score of 1, but did not have at least 25% reduction in
ABC-Irritability. All families chose to continue aripiprazole at the
end of this open label study, lending further evidence of the real-
world effectiveness of this treatment. Treatment did not raise pro-
lactin levels (they decreased - 3.6 [95%CI: - 5.5, - 1.8] p = 0.001),
but aripiprazolewas associatedwith 2.6 kg (95%CI: 1.3, 3.8)weight
gain (average starting weight was 42.6 kg– 3.7, and end-point
weight was 45.2 kg – 3.7 [p = 0.0006]). Liver functions were not
elevated, nor were Hg A1C or blood pressure, at end-point. One
subject had abnormal involuntary movements that were not tardive
dyskinesia and were nonepileptiform in nature. There were no ep-
isodes of neuroleptic malignant syndrome or tardive dyskinesia
observed. Youth were likely to report sedation, however. Although
this study was limited by the sample size and was not placebo
controlled or randomized, it was intensive in nature in terms of
systematically assessing response and side effects.
Subjects treated with aripiprazole tolerated the medication well,
and the results presented here show a slightly higher magnitude of
symptom reduction than the 2012 Cochrane Collaborative meta-
analysis regarding aripiprazole for ASDs (Ching and Pringsheim
2012). This may be because our protocol allowed for higher doses
(up to 20mg/day) and was slightly longer in duration; 12 weeks as
opposed to 8. This is in comparison with data pooled from 316
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children (taken from two randomized placebo- controlled trials of 8
weeks’ duration by Shea et al. [2004] andOwen et al. [2009]). In that
pooled study, they noted that ABC-irritability subscale scores de-
creased by 6.17 (95%CI: 9.07,-3.26), although they only observed a
weight gain of 1.13 kg (95% CI: 0.71, 1.51) in 8 weeks. Doses in the
Owen study were most likely to be 15mg by the end of the study
(26 of the 36 youth were at this dose at end-point). Doses in the
Ching pooled data were described in terms of impact on the ABC-
Irritability scores (5mg/day, reduced by - 12.4; 10mg/day, reduced
by - 13.2; 15mg/day, reduced by - 14.4; versus placebo, - 8.4; all
p< .05). Across the studies in the Cochrane review, common side
effects included weight gain, sedation, and tremor (relative to pla-
cebo), which are similar to our findings. We conclude that over 12
weeks, more symptom reduction is possible in this population, but
with it may come metabolic risks, such as weight gain.
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Table 1. Symptom Ratings at Baseline and End-Point Over 12 Weeks
Baseline Mean – SE End-point Mean – SE
Change
Mean (95%CI) p value
YBOCS
Severity 3.0 – 0.5 1.8 – 0.4 - 1.2 (- 2.4, - 0.0) 0.04
Reliability 0.9 – 0.1 0.9 – 0.1 0.0 (- 0.3, 0.3) 0.9
Obsessions 7.2 – 1.8 6.2 – 1.5 - 1.0 (- 4.9, 2.9) 0.6
Compulsions 9.3 – 1.6 4.6 – 1.4 - 4.7 (- 7.7, - 1.7) 0.006
Total 15.9 – 2.6 10.2 – 2.0 - 5.7 (- 10.6, - 0.8) 0.03
ABC
Irritability 24.5 – 2.9 6.8 – 2.0 - 17.7 (- 22.0, - 13.3) < 0.0001
Lethargy 15.0 – 2.7 5.1 – 1.4 - 9.9 (- 16.2, - 3.6) 0.005
Stereotypy 8.1 – 1.8 1.8 – 0.8 - 6.4 (- 10.1, 2.7) 0.003
Hyperactivity 27.9 – 3.2 6.7 – 1.9 - 21.2 (- 26.9, - 15.6) < 0.0001
Inappropriate speech 6.4 – 1.0 2.2 – 0.6 - 4.3 (- 5.9, - 2.7) < 0.0001
BPRS
Total 69.0 – 4.7 36.1 – 4.1 - 32.9 (- 44.7, - 21.1) < 0.0001
YBOCS, Yale–Brown Obsessive Compulsive Scale; ABC, Aberrant Behavior Checklist; BPRS, Brief Psychiatric Rating Scale.
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